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Background {#sec005}
==========

Heart disease remains the major public health concern and leading cause of death worldwide. Cardiovascular diseases (CVDs) accounted for nearly 836,546 deaths in the USA, out of which 9% was due to heart failure (HF) \[[@pone.0237781.ref001]\]. According to the American Heart Association (AHA) projection, future direct medical costs of HF would increase from \$31 billion in 2012 to \$70 billion in 2030 \[[@pone.0237781.ref002]\]. Death due to CVDs also takes place in low- and middle-income countries and sub-Saharan Africa (SSA), contributing to 5.5% of the global CVD deaths \[[@pone.0237781.ref003]\]. Data from different parts of Ethiopia also showed that CVD was the leading cause of death from non-communicable disease \[[@pone.0237781.ref004], [@pone.0237781.ref005]\].

HF is caused by any structural or functional cardiac abnormality, resulting in impairment of ventricular filling or ejection of blood \[[@pone.0237781.ref006]\]. HF is caused by various etiologies, each requiring unique management. The vast majority of HF in SSA are due to non-ischemic causes \[[@pone.0237781.ref007]\].

Neuro-hormonal antagonists and evidence-based beta-blockers have been shown to improve survival in patients with HF-with reduced ejection fraction (HFrEF) \[[@pone.0237781.ref008]\]. However, no treatment has yet been convincingly shown to reduce morbidity or mortality in HF with preserved ejection fraction (HFpEF) or HF with mid-range ejection fraction (HFmrEF) patients. In fact, the management of HFpEF is focused on managing congestion and comorbid conditions \[[@pone.0237781.ref009]\].

The care of HF patients is commonly complicated by the presence of comorbidity and poly-pharmacy, which in turn intensify risk of occurrence of drug therapy problems (DTPs) \[[@pone.0237781.ref010], [@pone.0237781.ref011]\]. A DTP is any undesirable event or circumstance experienced by a patient that involves, or is suspected to involve, drug therapy, and that interferes with achieving the desired goals of therapy. \[[@pone.0237781.ref012]\]. The occurrence of DTP may compromise treatment effectiveness and reduce quality of life \[[@pone.0237781.ref013]\]. Various studies showed that DTPs are the dominant reason for hospital admission and emergency department visits \[[@pone.0237781.ref014]--[@pone.0237781.ref016]\]. HF patients are at high risk of having DTPs \[[@pone.0237781.ref017]\] and frequencies as high as 78% have been reported \[[@pone.0237781.ref018]\]. The increased number of drugs prescribed has an important impact on HF patients, as it is associated with frequent hospitalization, waste of resources, adverse drug events, potential drug-drug interactions, and poor patient compliance \[[@pone.0237781.ref011], [@pone.0237781.ref019]--[@pone.0237781.ref021]\].

Patient satisfaction is an important measure of healthcare quality, as it offers information on the provider's success in meeting clients' expectations \[[@pone.0237781.ref022]\]. Low patient satisfaction may result in loss of trust and consequently in changing treating physicians or healthcare facilities or even discontinuing treatment \[[@pone.0237781.ref023]\]. Evaluating to what extent patients are satisfied with health services is clinically relevant, as satisfied patients are more likely to comply with treatment \[[@pone.0237781.ref024]\].

Optimization of drug therapy and prevention of DTPs are major factors for improving health care, reducing expenditure, and saving lives \[[@pone.0237781.ref025]\]. In practice, most HF patients are treated as outpatients, and their care in this setting is challenging, because less time is available for outpatient evaluation, and much more reliance is placed on appointment visits. Early identification of DTPs therefore helps to prevent and manage them through developing a better care plan. Studies regarding DTPs and patient satisfaction in ambulatory HF patients are limited in Ethiopia. Thus, the present study aimed to assess DTPs and patient satisfaction among ambulatory HF patients in a tertiary care teaching hospital of Ethiopia.

Methods {#sec006}
=======

Study setting {#sec007}
-------------

The study was conducted in the adult cardiac clinic of Tikur Anbessa specialized Hospital (TASH), the largest tertiary care teaching hospital of the country, with 700 bed capacity. Adult cardiac clinic is one of the many chronic follow-up clinics of the hospital giving service four days per week and manned by cardiologists, cardiology fellows, residents and nurses.

Patients' involvement {#sec008}
---------------------

Patients did not participate in conception and design of the study. However, they provided input during the pre-test (5% of the sample size), which helped us to make changes in the patient approach and timing for an interview during data collection. Patients played a central role in determining the level of medication adherence and treatment satisfaction.

Study design and study period {#sec009}
-----------------------------

A prospective cross-sectional study design was employed and carried out from 20 June to 20 August 2017 at the adult cardiac clinic of TASH

Study population and inclusion criteria {#sec010}
---------------------------------------

Participants were all HF patients on follow up during the study period and who fulfilled the inclusion criteria. Patients aged ≥14 and diagnosed with HF, on active follow up and receiving treatment for at least 6 months, and had complete medical records including echocardiography findings were included. Patients with decompensated mitral stenosis (MS), missing (incomplete) data and not willing to participate were excluded.

Sample size determination and sampling technique {#sec011}
------------------------------------------------

Sample size (n = 423) was calculated using single population proportion formula. Since there was no previous study done on DTP among HF patients in Ethiopia, the proportion (P) of DTP in HF patients was taken as 50%. Systematic random sampling was used to select study participants. Following determination of sampling fraction, the first patient was selected randomly and every 3^rd^ patient was included in the study. For those who had repeated clinic visits during the study period, data were collected only during their first visit.

Data collection management {#sec012}
--------------------------

Structured questionnaire was used by two nurses for patient interview to obtain demographic data and clinical characteristics related to duration of treatment, frequency of hospital admission and current symptoms. Two clinical pharmacists reviewed patient charts for etiology of HF, echocardiographic parameters, NYHA functional class, comorbidities, history of allergies, vital signs, pertinent laboratory values, relevant past medical and medication history and current medications. Key informant interview was also administered for 6 physicians.

Appropriateness of medical treatment was evaluated using most updated guidelines of European Society of Cardiology and American Heart Association. The last three records of NYHA class, blood glucose and blood pressure were considered for identification of DTPs. Drug-drug interactions (DDIs) were evaluated using Micromedex^®^ (Micromedex 2.0, Truven Health Analytics Inc.) and only absolute contraindications and major drug interaction were considered. The identified DTPs were classified using Cipolle *et al*. (2012) DTP registration format.

Level of adherence was separately assessed using the Morisky Green Levin Medication Adherence Scale (MGL). Thus, patients were considered adherent if the score was ≤2 and non-adherent if the score was \>2. Patient satisfaction was assessed using Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) composed of 17 items with 6 (domains) dimensions. Satisfaction with each of the specific domains was scored using a five-point Likert scale and a score of \>50 was considered as satisfied.

Pretest on 5% of the sample size was performed to check for uniformity and understandability of the data collection instrument and the tool was modified accordingly. One day training was given to data collectors and daily supervision was carried out to ensure accuracy and consistency of collected data.

Data analysis {#sec013}
-------------

The data was entered into EPI-info V.7.2.1 and analyzed using Statistical package for social sciences (SPSS) version 21. Descriptive statistics was used to summarize patient characteristics. Categorical variables were described by frequencies and percentages and continuous variables by mean and standard deviations. A bivariate analysis was performed to identify determinants and variables with a p value\<0.25 were included in the multivariate analysis to control confounding factors. Odds ratio (OR) with 95% confidence interval was computed for each variable and a p value \<0.05 was considered as significant. Drug risk ratio (frequency of involvement in DTP divided by frequency of prescription) was used to identify drugs with high risk for creating DTPs.

Ethical considerations {#sec014}
----------------------

Ethical clearance was obtained from the Ethical Review Committee of School of Pharmacy as well as the Research and Ethics Committee of Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa University. Participants were informed about the objective, benefit and risk of the study. This was followed by obtaining a written consent (for ≥18 years old) and assent as well as consent from the parent/guardian for those \<18 years of age. Confidentiality and privacy were maintained through anonymity and restricting data access. The proposal including Amharic written verbal consent, which was attached as an annex was submitted to the Institutional Review Board (IRB) for approval. The study was conducted after obtaining a letter of approval from the School of Medicine (AAUMF 03--008) as well as the School of Pharmacy (002/17/SPharma) Boards.

Results {#sec015}
=======

Demographic characteristics of patients {#sec016}
---------------------------------------

Mean age of the patients was 46.52±17, with a range of 14 and 90 years. The female gender was relatively high (53%) than the male gender. About two-third (64%) of them were married and about one-third (31.4%) had no formal education. Majority of the patients (90.5%) didn't use any of the social drugs and more than half (54%) of them paid out of pocket for their medications ([Table 1](#pone.0237781.t001){ref-type="table"}).

10.1371/journal.pone.0237781.t001

###### Socio-demographic characteristics of heart failure patients attending at the cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, June---August, 2017.

![](pone.0237781.t001){#pone.0237781.t001g}

  Socio demographic                          Category              Number (%)   Mean ± SD   Range
  ------------------------------------------ --------------------- ------------ ----------- -------
  **Gender**                                 Male                  200 (47.3)               
  Female                                     223 (52.7)                                     
  **Age**                                    14--35                111 (26.2)               
  36--60                                     2 14(50.6)            46.52±17     14--90      
  \>60                                       98 (23.2)                                      
  **Marital status**                         Single                105 (24.8)               
  Married                                    270 (63.8)                                     
  Divorced                                   17 (4)                                         
  Widowed                                    31 (7.3)                                       
  **Educational status**                     No formal education   133(31.4)                
  Primary                                    126(29.8)                                      
  Secondary                                  120 (28.4)                                     
  Diploma and above                          44 (10.4)                                      
  **Social drug use**                        Cigarette Smoking     3 (0.7)                  
  Alcohol use                                21(5)                                          
  Khat chewing                               14 (3.3)                                       
  **Hospitalization in the past one year**                         156(36.9%)               
  **Source of medication**                   Free                  196 (46.3)               
  Paid                                       227 (53.7)                                     

Clinical characteristics of patients {#sec017}
------------------------------------

The commonest cause of HF was chronic rheumatic valvular heart disease (CRVHD) (50.8%). Isolated valves were involved in 108 (50.2%) and multiple valves in 107 (49.8%) of the cases. A combination of mitral stenosis (MS) and mitral regurgitation (MR) was observed in 48 patients, while 40 patients had an isolated MR ([Fig 1](#pone.0237781.g001){ref-type="fig"}). Mean duration of treatment for HF was 6 ±4.6 years. Over half (55.6%) of the patients were in NYHA Class III and two-third (66.2%) of them had a preserved systolic function. Almost all (98.8%) patients reported no experience of drug allergy. Comorbidity was found in 318 (75.2%) of the patients, with hypertension and atrial fibrillation accounting for 40.9% and 37.4%, respectively ([Table 2](#pone.0237781.t002){ref-type="table"}).

![Common valve lesions observed among heart failure patients attending at the cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia June---August, 2017.\
AR: Aortic Regurgitation, AS: Aortic Stenosis, MR: Mitral Regurgitation, MS: Mitral Stenosis, TR: Tricuspid Regurgitation.](pone.0237781.g001){#pone.0237781.g001}

10.1371/journal.pone.0237781.t002

###### Clinical characteristics of heart failure patient attending at the cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia June---August, 2017.
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  Clinical CXS                          Category        Number (%)    Mean ± SD      Range
  ------------------------------------- --------------- ------------- -------------- --------
  Cause of heart failure                CRVHD           215(50.8)                    
  IHD                                   (91)21.5                                     
  HHD                                   62(14.7)                                     
  CMP                                   (45)10.6                                     
  Others                                (10)2.4                                      
  Duration of heart failure treatment   ≤5years         235(55.5)                    
  6-10yrs                               135(32)         6 ±4.6        6month-35yrs   
  \>10yrs                               53(12.4)                                     
  Frequency of follow up                ≤3 month        316(74.7)                    
  ≥4 month                              107 (25.3)                                   
  NYHA class                            Class I         63 (14.9)                    
  Class II                              125 (29.6)                                   
  Class III                             235 (55.6)                                   
  LVEF                                  HFrEF (\<40%)   104 (24.9%)   55.43±14.4     15--81
  HFmrEF (40--49%)                      39 (9.2%)                                    
  HFpEF (≥50%)                          280 (66.2%)                                  
  Known drug allergy                    No              418 (98.8)                   
  Yes                                   5 (1.2)                                      
  Comorbidity                           Hypertension    (173)40.9                    
  Atrial fibrillation                   (158)37.4                                    
  Diabetes mellitus                     (67)15.8                                     
  Dyslipidemia                          (26)6.1                                      
  Asthma                                (21)5                                        
  Stroke                                (18)4.3                                      
  Peripheral neuropathy                 (11)2.6                                      
  Others                                (38)9                                        

\*Other: Degenerative valvular heart disease, corpulomonale, congenital heart disease; CMP: cardiomyopathy, CRVHD: chronic rheumatic valvular heart disease, IHD: ischemic heart disease, HHD: hypertensive heart disease, HFrEF: heart failure with reduced ejection fraction, HFmrEF: heart failure with mid-range ejection fraction, HFpEF: heart failure with preserved ejection fraction, LVEF: left ventricular ejection fraction.

Patient characteristic was related to causes of HF and disaggregation revealed that patients with CRVHD (33.7%) classified mainly under the ages of 36--60 years and IHD (12.0%) for \> 60 years ([Table 3](#pone.0237781.t003){ref-type="table"}).

10.1371/journal.pone.0237781.t003

###### Disaggregation of type of patient characteristics with causes of heart failure in patients attending at the cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia June---August, 2017.
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  Variables                 CRVHD    IHD   HHD   CMP   Others   
  ------------------------- -------- ----- ----- ----- -------- ---
  Age                       14--35   16    1     \-    10       1
  36--60                    98       42    15    20    2        
  \>60                      12       35    22    13    4        
  Gender                    Male     31    48    15    21       1
  Female                    95       30    22    22    6        
  Systolic BP               \<120    119   \-    \-    25       7
  120--129                  7        72    16    12    \-       
  130--139                  \-       5     14    6     \-       
  ≥140                      \-       1     7     \-    \-       
  Comorbidity               Yes      117   76    37    37       6
  N[o]{.ul} of medication   \<5      20    10    7     6        4
  ≥5                        106      68    30    37    3        

CMP: cardiomyopathy, CRVHD: chronic rheumatic valvular heart disease, IHD: ischemic heart disease, HHD: hypertensive heart disease.

In an attempt to look at the contribution of the different etiologies to HF with time, the data was disaggregated. The analysis showed that 235 (55.5%) patients had had HF for ≤ 5 years, out of which 48.5% had CRVHD, 22.9% ischemic heart disease (IHD), and 13.6% hypertensive heart disease (HHD). The number of patients having the three etiologies decreased with duration HF ([Table 4](#pone.0237781.t004){ref-type="table"}).

10.1371/journal.pone.0237781.t004

###### Disaggregation of duration of heart failure with etiology among patients attending at the cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia June---August, 2017.
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  Etiology of HF   Duration of heart failure                             
  ---------------- --------------------------- ------------- ----------- -----
  CRVHD            114 (53%)                   74(34.4%)     27(12.6%)   215
  IHD              54 (59.3%)                  30 (32.9%/)   7 (7.7%)    91
  HHD              32 (51.6%)                  15            15          62
  CMP              31 (68.9%)                  11 (24.4%)    3 (6.7%)    45
  Others           4 (40%)                     5 (50%)       1 (10%)     10
  Total            235                         135           53          423

CMP: cardiomyopathy, CRVHD: chronic rheumatic valvular heart disease, IHD: ischemic heart disease, HHD: hypertensive heart disease.

A large proportion (63.4%) of patients received 5--10 drugs per day and mean number of drugs per day was 4.96±1.62 per patient. A total of 2097 medications were prescribed and diuretics (27.6%) and beta blockers (14.5%) were the commonly prescribed drug classes. The most frequently prescribed specific drugs were furosemide (294), spironolactone (236), enalapril (188), benzathine penicillin (181), aspirin (171) and atenolol (170) ([Fig 2](#pone.0237781.g002){ref-type="fig"}).

![Frequently prescribed drug class in heart failure patients attending at the cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia June-August, 2017.\
Anti arrhythmic, antianginal agent, antithyroid, antiTB, HAART, Iron salt, NSAIDs, xanthine oxidase inhibitor, tricyclic antidepressant; ACIEs: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers, CCBs: calcium channel blockers, OHA: oral hypoglycemic agents.](pone.0237781.g002){#pone.0237781.g002}

Prevalence and type of DTPs {#sec018}
---------------------------

A total of 730 DTPs were identified in 291(68.8%) patients. One DTP was identified in 46 (15%), 2 in 85 (29.2%), three in 93 (31.9%) and ≥ 4 in 67(23%) patients. The average number of DTP per patient was 2.51±1.068.

The most common DTPs identified were drug-drug interactions (DDI) (27.3%) followed by noncompliance (26.2%), ineffective drug (13.7%), adverse drug reaction (ADR) (11.5%) and need additional drug therapy (9.4%) ([Table 5](#pone.0237781.t005){ref-type="table"}). The most frequent drug classes involved in DTPs were beta blockers followed by angiotensin converting enzyme inhibitors (ACEIs), and mineralocorticoid receptor antagonist (MRA) ([Fig 3](#pone.0237781.g003){ref-type="fig"})

![Drug classes involved in specific type of drug therapy problems among heart failure patients attending at the cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia June---August, 2017.](pone.0237781.g003){#pone.0237781.g003}

10.1371/journal.pone.0237781.t005

###### Type of DTP identified from heart failure patients attending at the cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia June---August, 2017.
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  Type of DRP                    Specific DTP            No     Percent
  ------------------------------ ----------------------- ------ ---------
  Drug interaction                                       199    27.3
  Adverse drug reaction          Undesired effect        74     11.5
  Unsafe drug for the patient    5                              
  Allergic reaction              5                              
  Effectiveness                  Ineffective drug        100    13.7
  Inappropriate dose             Suboptimal dose         52     7.1
  Dose high                      4                       0.55   
  Need additional drug therapy   Prophylactic            55     7.5
  Synergy                        14                      1.92   
  Unnecessary drug therapy       No medical indication   17     2.3
  Compliance                     Non drug therapy        14     1.92
  Non compliance                 191                     26.2   

Prevalence of DTP was related to causes of HF and disaggregation revealed that patients with CRVHD (38.6.%) had the highest DTP followed by IHD (32.8%) ([Table 6](#pone.0237781.t006){ref-type="table"}).

10.1371/journal.pone.0237781.t006

###### Disaggregation of type of drug therapy problems with causes of heart failure in patients attending at the cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia June---August, 2017.
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  Variables                              CRVHD   IHD   HHD   CMP   Others
  -------------------------------------- ------- ----- ----- ----- --------
  **Drug therapy problems**                                        
  N[o]{.ul} medical indication           \-      14    2     1     \-
  Non drug therapy more appropriate      13      \-    \-    \-    1
  Prophylactic/preventive drug therapy   15      25    3     12    \-
  Synergistic                            7       \-    7     \-    \-
  More effective drug available          23      50    5     18    4
  Dose low                               3       29    \-    20    \-
  Dose high                              4       \-    \-    \-    \-
  Adverse drug reactions                 36      22    21    4     1
  Drug interaction                       95      51    19    31    3
  Non compliance                         85      49    28    25    4

CMP: cardiomyopathy, CRVHD: chronic rheumatic valvular heart disease, IHD: ischemic heart disease, HHD: hypertensive heart disease.

A total of 199 significant DDIs were identified. At least one drug interaction (DI) was found in 141, 2 in 42, and more than two in 16 patients. The commonest DDI found was the use of spironolactone and digoxin with arbitrary monitoring of potassium level. Such use might have resulted in increased digoxin toxicity.

About 20% (n = 84) of patients experienced medication adverse effects. These included gum bleeding due to warfarin (22); dry cough (20) and angioedema (1) due to ACEIs; and peripheral edema due to nifedipine (11). Other ADRs reported were penicillin allergy, upper gastrointestinal bleeding (UGIB) due to dual antiplatelet therapy, atenolol induced bradycardia and bronchospasm & hypotension due to high dose of furosemide, myopathy related to atorvastatin and spironolactone induced gynecomastia and hyperkalemia.

Drug risk ratio was calculated for each drug. A higher drug risk ratio was found for Nifedipine (0.7) followed by Metoprolol tartrate (0.6), Atenolol (0.33) and Enalapril (0.25). Although furosemide was the most frequently used, it was found to have a lowest drug risk ratio (0.07).

According to the MGL medication adherence scale, 191 (26.2%) of patients were non-adherent to their medication. Reason for non-adherence included forgetfulness (43.5%), regimen complexity (40%), unavailability of medication (22.3%), worsening of symptoms (19.6%), drug side effect (19.3%) and cost of medication (14.9%).

Predictors of DTP {#sec019}
-----------------

Variables with p value \< 0.25 in the bivariate analysis and included in the multivariate logistic regression were age, gender, marital status, educational status, NYHA class, left ventricular ejection fraction (LVEF), presence of comorbidity, duration of HF treatment, source of medication and number of medications. Subsequent analysis with multivariable logistic regression revealed that age, NYHA class, LVEF, presence of comorbidity, duration of HF treatment, source of medication and average number of drugs/day were significantly associated with DTP ([Table 7](#pone.0237781.t007){ref-type="table"}). Patients aged between 36--60 years were 4.8 times more likely (AOR = 4.8, 95% CI 1.804--12.806) to develop DTPs compared to patients with \<35 years of age. NYHA class III patients had 5.6 times more chance (AOR = 5.65, 95% CI 2.714--11.768) to develop DTPs compared to NYHA class I or class II patients. Patients with reduced ejection fraction were 6.2 times more likely (AOR = 6.23, 95% CI 23.90--16.245) to develop DTPs than patients with preserved ejection fraction. The odds of DTP among patients with one or more co-morbidities was 5.2 times higher (AOR = 5.23, 95% CI 1.032--7.196) than those with no co-morbidities. The odds of DTPs were 7 times higher (AOR = 7, 95% CI 3.263--15.280) among patients taking an average of 5 or more drugs per day as compared to those less than five drugs per day.

10.1371/journal.pone.0237781.t007

###### Predictors of occurrence of drug therapy problems in heart failure patients attending the cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia June---August, 2017.

![](pone.0237781.t007){#pone.0237781.t007g}

  Variables                            Category          DTPs (%)    COR (95% CI)            AOR (95% CI)                                                 
  ------------------------------------ ----------------- ----------- ----------------------- ------------------------------------------------------------ ---------------------
  Gender                               Male              115(39.5)   85(64.4)                1.00                                                         1.00
  Female                               176(60.5)         47(35.6)    2.76(1.806--4.241)      1.54(0.737--3.216)                                           
  Age                                  14--35            28(9.6)     83(62.9)                1.00                                                         1.00
  36--60                               178(61.2)         36(27.3)    14.65(8.386--25.617)    4.80(1.804--12.806) [\*](#t007fn001){ref-type="table-fn"}    
  \>60                                 85(29.2)          13(9.8)     19.38(9.397--39.978)    3.45 (1.017--11.71) [\*](#t007fn001){ref-type="table-fn"}    
  Marital status                       Ever married      232(79.7)   86(65.2)                1.00                                                         1.00
  Single                               59(20.3)          46(34.8)    0.47(0.301--0.752)      2.015(0.793--5.120)                                          
  Educational                          Primary or less   185(63.6)   74(56.1)                1.368(0.900--2.079)                                          2.138(0.949--4.817)
  Secondary and above                  106(36.4)         58(43.9)    1.00                    1.00                                                         
  NYHA class                           Class I-II        76(26.1)    112(84.8)               1.00                                                         1.00
  Class III                            215(73.9)         20(15.2)    15.84(9.205--27.265)    5.65(2.714--11.768) [\*](#t007fn001){ref-type="table-fn"}    
  Left ventricular ejection fraction   HFpEF             195(67)     124(93.9)               1.00                                                         1.00
  HfrEF                                96(33)            8(6.1)      7.63(3.585--16.244)     6.23(2.390--16.245) [\*](#t007fn001){ref-type="table-fn"}    
  Comorbidity                          No                18(6.2)     87(65.9)                1.00                                                         1.00
  Yes                                  273(93.8)         45(34.1)    2.93(2.864--11.386)     5.23(1.032--7.196)[\*](#t007fn001){ref-type="table-fn"}      
  Source of med                        Paid              147(50.5)   80(60.6)                1.00                                                         1.00
  Free                                 144(49.5)         52(39.4)    1.507(0.992--2.289)     2.32 (1.105--4.860)[\*](#t007fn001){ref-type="table-fn"}     
  Duration of HF                       ≤5yrs             128(44)     107(81nm.1)             1.00                                                         1.00
  6--10                                114(39.2)         21(15.9)    4.538(2.667--7.722)     1.097(1.009--1.193) [\*](#t007fn001){ref-type="table-fn"}    
  \>10                                 49(16.8)          4(3)        10.24(3.580--29.29)     4.415(1.190--16.375) [\*](#t007fn001){ref-type="table-fn"}   
  Number of medications                \<5               47(16.2)    108(81.8)               1.00                                                         1.00
  ≥5                                   244(83.8)         24(18.2)    23.36(13.595--40.145)   7(3.263--15.280)[\*](#t007fn001){ref-type="table-fn"}        

\* Statistically significant at P-value \< 0.05; AOR = Adjusted odds ratio; COR = Crude odds ratio, HFpEF: heart failure with preserved ejection fraction, HFrEF: heart failure with reduced ejection fraction.

Patient satisfaction {#sec020}
--------------------

The satisfaction score for undesirable side effect and treatment effectiveness was 79% and 70%, respectively. However, the score for impact on daily activity was relatively lower, standing at 62%. The global satisfaction score was 78% and the overall mean score of treatment satisfaction was 60.5(SD, 10.5) ([Table 8](#pone.0237781.t008){ref-type="table"}).

10.1371/journal.pone.0237781.t008

###### The treatment satisfaction of heart failure patients attending cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia June---August, 2017.
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  SATMED-Q dimension                    Satisfaction score (Mean ± SD)
  ------------------------------------- --------------------------------
  Undesirable side effects (0--100)     79.3± 27.2
  Treatment effectiveness (0--100)      70.5 ± 14.0
  Convenience of use (0--100)           59.9 ± 20.6
  Impact on daily activities (0--100)   70.6 ± 16.2
  Medical care (0--100)                 63.5 ± 19.2
  Global satisfaction (0--100)          78.7 ± 20.1
  Total composite score (0--100)        60.5 ± 10.5

Discussion {#sec021}
==========

HF patients are at high risk of having DTPs and adherence issues due to comorbidity, polypharmacy and complexity of drug regimens. The presence of DTPs in patients with HF is associated with detrimental health outcomes. Identification of type of DTP and factors associated with them is therefore critical for prevention of DTPs and improving health outcomes.

There was a female preponderance in HF in the present study, which is in agreement with studies performed elsewhere \[[@pone.0237781.ref013], [@pone.0237781.ref019], [@pone.0237781.ref025]\]. HF appears to be more common in the adult population, as the mean age was 46.5 (SD 17) and 50.6% of them were in the age group of 36--60 years. This is in line with other local studies \[[@pone.0237781.ref026], [@pone.0237781.ref027]\]. As age increases, the number of medications and comorbidities were increased and also limit patients' physical activity. The number of comorbidities (75%) was found to be lower than other studies \[[@pone.0237781.ref028], [@pone.0237781.ref029]\]. The possible reason for this difference could be related to age difference of patients involved in the studies.

A total of 2097 drugs were used with a mean of 4.9 drugs per patient. This is comparable with some studies \[[@pone.0237781.ref028], [@pone.0237781.ref029]\] but different from other studies \[[@pone.0237781.ref017], [@pone.0237781.ref018]\], where a mean of \>10 drugs/patient were prescribed. In the latter studies, more than 80% of the patients had comorbidities like hypertension and diabetes mellitus that required multiple therapies.

The prevalence of DTP obtained in the present study (69%) is in line with those reported in cardiovascular patients of India (66.3%) \[[@pone.0237781.ref030]\], Switzerland (69%) \[[@pone.0237781.ref031]\] and Gondar, Ethiopia (63.4%) \[[@pone.0237781.ref019]\]. However, it was lower than other rates reported from Barcelona (78%) \[[@pone.0237781.ref018]\] and Bonga, Ethiopia (72%) \[[@pone.0237781.ref032]\]. Difference in the study design (cohort vs cross sectional study), classification and operationalization of DTP, and nature of patients included in the study could explain the discordance.

Consistent to other studies \[[@pone.0237781.ref013], [@pone.0237781.ref018], [@pone.0237781.ref030]\], DDI was the most commonly encountered DTP. DDI is known to be a major factor affecting patient's clinical outcome by contributing to increased risk of adverse drug events related to hospitalization and a higher health care cost. Adherence related problem was the second most common DTP (26.2%) and found to be concordant with other rates reported India (28.9%) \[[@pone.0237781.ref033]\] and the Netherlands (28%) \[[@pone.0237781.ref034]\]. Higher rates than the current study had been reported from Cuba (36.5%) \[[@pone.0237781.ref035]\], Adama (Ethiopia) (44.8%) \[[@pone.0237781.ref013]\], Jimma (Ethiopia) (46.4%) \[[@pone.0237781.ref029]\] and Brazil (63.5%) \[[@pone.0237781.ref036]\]. Variation in the setting (outpatient vs. inpatient), methods used to measure adherence, or severity of the disease might account for the observed difference.

Problems related to drug effectiveness (13.7%) was the third most common DTP identified. Use of Aspirin instead of warfarin for prevention of stroke in patients with atrial fibrillation was one of the problems detected. However, guidelines state that aspirin is less effective in preventing stroke than warfarin \[[@pone.0237781.ref006]\]. Physicians cited different reasons for use of aspirin, including unavailability of warfarin, unaffordability and inaccessibility of INR monitoring. The other effectiveness problem was the use of Atenolol and Metoprolol tartrate in patients with HFrEF. The efficacy of Metoprolol tartrate in reducing mortality in HF has not been proven \[[@pone.0237781.ref002], [@pone.0237781.ref008]\]. Moreover, Metoprolol succinate provides more consistent plasma concentrations over a 24 h period compared to the immediate-release Metoprolol \[[@pone.0237781.ref037]\]. The reason for not using Metoprolol succinate was related to availability and cost.

ADRs were identified in 11.5% of the patients. A similar rate was reported from a Taiwan study (13.5%) \[[@pone.0237781.ref017]\], although higher rates were also reported from India (19%) \[[@pone.0237781.ref038]\] and Ethiopia (26%) \[[@pone.0237781.ref029]\]. Inappropriate dosing (suboptimal dose and dose high) accounted for 7.65% of all DTPs, where suboptimal dosing was observed in 7.1% of patients. This is concordant with studies done in Spain (6.7%) \[[@pone.0237781.ref028]\], India (10.4%) \[[@pone.0237781.ref030]\], and Ethiopia (7.5%) \[[@pone.0237781.ref029]\]. ACEIs and evidence based β blockers were found to be not titrated towards established guideline recommended target doses. Presence of other comorbidities, fear of adverse effects, reluctance to change the treatment when patients are stable, burden of monitoring, and lack of clinical experience were cited as reasons for failure to up-titrate the dose. On the other hand, dose high was observed only in four patients, unlike other studies \[[@pone.0237781.ref017], [@pone.0237781.ref029], [@pone.0237781.ref039]\], where higher rates were reported. The most common drug associated with high dose was furosemide, which led patients to experience hypotension.

Among indication related problems, the need for prophylactic/preventive drug therapy accounted for 7.5%, which was in line with studies conducted in Taiwan (7%) \[[@pone.0237781.ref017]\], Jordan (7.6%) \[[@pone.0237781.ref025]\] and India (9.4%) \[[@pone.0237781.ref038]\], those higher rates were reported from Barcelona (28.6%) \[[@pone.0237781.ref018]\] and Boston 43% \[[@pone.0237781.ref039]\]. Participants' level of education and awareness, the health care system and resources allocated, patient information regarding active disease, laboratory values and medications used would likely contribute the difference. Indeed, such factors could create opportunities for easy identification of DTPs and co-morbidities in HF patients. ACEIs and β blockers were among the most common drug categories needed for the prevention of cardiac remodeling and disease progression and this is in line with other local studies \[[@pone.0237781.ref029]\]. Unnecessary drug therapy was found in 4.2% of patients. Lower \[[@pone.0237781.ref025]\] and similar \[[@pone.0237781.ref018]\] rates to the current study have been reported in the literature.

Beta blockers, ACEIs, MRA and antiplatelet were among the common drug classes involved in DTP as reported elsewhere \[[@pone.0237781.ref017], [@pone.0237781.ref018], [@pone.0237781.ref030], [@pone.0237781.ref032]\]. It is essential to be aware of and give due attention to those drugs with the highest drug risk ratio, as they could expose patients more often to DTPs.

Identification of risk factors for DTPs is important to identify the most susceptible patients requiring close monitoring of drug therapy. Age, NYHA class, LVEF, presence of comorbidity, duration of HF treatment, source of medication and poly-pharmacy were found to be independent predictors DTPs. These findings are supported by a number of other studies \[[@pone.0237781.ref018], [@pone.0237781.ref019], [@pone.0237781.ref028], [@pone.0237781.ref038]\]. As age increases, comorbidity and number of medication increase, exposing patients to an increased risk for developing DTPs. Patients with reduced ejection fraction are at higher risk for developing DTPs. This could be because patients with reduced ejection fraction might not be on cardio protective medication (untreated medical condition) or may be on suboptimal dose.

Satisfaction with medication and medical treatment appears to be related to patient medication adherence, and constitutes a quality indicator that can be used for improving health care. Patient satisfaction influences the health behavior and would be crucial in patients with chronic diseases \[[@pone.0237781.ref040]\]. Global satisfaction of study participant was 78% and this congruent with scores reported from Greece (80%) \[[@pone.0237781.ref041]\] and Nigeria (78.6%) \[[@pone.0237781.ref042]\]. The overall mean score of treatment satisfaction (60.5%) is also a similar study \[[@pone.0237781.ref043]\] carried out in HF patients (over 60%). A lower score was found in the undesirable side effect domain (21%) and the score for satisfaction on convenience of use was also relatively lower (59%) compared to other dimensions. Lower score in the convenience domain compared to other dimensions is also reported \[[@pone.0237781.ref040]\] and might be attributed to pill burden that poses difficulty to adhere to dose regimens.

This study has some limitations. The cross-sectional nature of the study didn't allow follow up of patients and it was also a non-interventional study. No causal relationship had been established when ADRs were identified. Self- reporting was used to measure adherence, which may suffer from recall bias, and hence could overestimate the level of adherence. In addition, the extent of generalisablity may be limited, since it was a single centered study conducted in a tertiary care hospital, where complicated and severe cases that might need combination therapy are referred. Nevertheless, the higher sample size, randomized sampling techniques, use of both patient interview and medical chart review could offset these limitations.

Conclusions {#sec022}
===========

Medication therapy plays a significant role in treating HF. However, optimal medication in HF outpatients remains to be a major challenge in clinical practice. This study provided evidence that several types of DTPs, including non-adherence are apparent among ambulatory HF patients and CRVHD appears to be the most common cause of the disease. Old Age, NYHA class, LVEF, comorbidity, duration of treatment, source of medication, and poly-pharmacy have been identified as predictors of DTPs. A relatively good global satisfaction of study participants was obtained. These issues should be appropriately addressed in order to improve the overall outcome of patients.
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:   Diabetes mellitus
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HFpEF
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HFrEF
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:   Hypertensive heart disease

HTN
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MGL

:   Morisky Green Levin Medication Adherence Scale
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:   New York heart association

RCT

:   Randomized control trials

RHD

:   Rheumatic heart disease

SSA

:   Sub-Sahran Africa
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TR
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it might have merit but does not meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please note that there are substantial changes required and your manuscript will only be considered if you can address them. In addition to the reviewer\'s comments, I would like you to particularly consider the following points:
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The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly
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2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors provide a cross-sectional analysis of DTPs in a subset of patients with presumed heart failure and conclude that the prevalence of DTPs and non-adherence among HF patients is high.

I have a number of comments:

1\) The authors state that the commonest cause of HF was chronic rheumatic valvular heart disease (CRVHD); namely in 50.8%. Please specify further: how many were mitral valve stenosis? how many were mitral valve regurgitation? or both? how many were aortic valve stenosis? etc.

This is of crucial importance because distinct myocardial structural and/or functional abnormalities will develop according to which type of valve is affected. For instance, in the setting of mitral valve stenosis, the LV is protected from pressure or volume loading and signs and symptoms of HF result from high pulmonary pressures without elevated ventricular pressures. Furthermore, patients with decompensated mitral valve stenosis do not fit in the chronic HF guideline drug therapy recommendations and therefore should not be included in this study. Indeed, these patients should receive diuretics, possibly rate control for atrial fibrillation, but above all mitral valve intervention.

Therefore, to obtain a more relevant (chronic HF) patient population, analyses should be more specific according to type of CRVHD.

2)If HF results from VHD, then a class I indication exists for valvular intervention. Please specify the reasons why this has not been performed.

3)Please specify the length of HF duration according to etiology of HF.

4)Generalizability is limited because of the relatively young age and high prevalence of CRVHD.

5)The authors state a prevalence of HFpEF of 66.2% in their group. However, this will be enriched with CRVHD patients (probably MV stenosis). This cannot be classified as HFpEF and should be changed.

6)Specify the reason for inappropriate dose (Table 3.): this could be because of uptitration phase, hypotension, renal insufficiency, bradycardia etc. Hence, this should not be recorded as a DTP perse.

7)Anecdotic interactions are scored as DTPs (such as diuretic with aspirin; or spironolactone with aspirin etc). In the setting of HF due to ischemic heart disease, these combinations are class I recommended. This should not be regarded as a DTP or DDI. Please adjust the data accordingly.

8)In the discussion the authors frequently refer to other papers. The HF populations described in these references however differ substantially in their characteristics with the currently studied patient population. Again, generalizability is limited, because of the very high prevalence of untreated CRVHD and young patient age.

9)The authors claim that the most frequent DDI was between aspirin and furosemide with increased risk of nephrotoxicity and reduced diuretic effectiveness. This again is anecdotic. Please provide data about the actual occurrence of aspirin/furosemide induced nephrotoxicity and reduced diuretic effectiveness.

10)Dual antiplatelet therapy is class I recommended in ACS patients. Therefore, this should not be regarded as a DDI. Please adjust. It is more relevant to depict the DTP\'s with actual relevant clinical impact.

11)Expand Table 4 with patient characteristics, such as age, comorbidities, gender, renal function (eGFR), blood pressure and medication

12)How many patients have been hospitalized for HF in the past?

13)Please have the manuscript reviewed by a native English speaker.
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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We would like to thank the Editor and reviewers for their critical comments and constructive suggestions, which contributed to the quality of the manuscript. We have revised the manuscript as advised and changes made are highlighted in yellow. Point-by-point response for the reviewers' comment is given below. We hope the revision undertaken has improved the manuscript to a level of your satisfaction and we request your editorial hand.

Response to Editorial Comments

Comment 1: Definition of DTP with supplementary table

Response 1: Accommodated.

Comment 2: Drug interaction as DTP since all top 5 drug interaction are clinically not relevant (hardly considered as DTP )

Response 2: Removed all the others except those associated with adverse drug reactions.

Comment 3: Clearly divide between HFrEF and HFmrEF

Response 3: Accommodated.

Comment 4: The discussion should be short and focused significantly

Response 4: Shortened as much as possible

Comment 5: Permission for MMA4

Response 5:- Since we did not hear from the License holder, we used the equivalent scale "the four --item Morisky Green Levin Medication Adherence Scale (MGL)" , which is a free online version.

Comment 6: Mention statistical analysis used

Response 6: We elaborated the statistical analysis used and also included in the abstract.

Response to Reviewer\' comments

Comment 1: Please specify further the types of valve involved in CRVHD patients

Response 1: The types of valve lesion involved are provided in a new Figure (Figure 1). Please take note that patients with decompensated MS were not included in the study.

Comment 2: If HF results from VHD, then a class I indication exists for valvular intervention. Please specify the reasons why this has not been performed.

Response 2: Valvular surgery was not provided when the study was initiated. It used to done through mission based aid or sponsor based travel abroad.

Comment 3: Please specify the length of HF duration according to etiology of HF.

Response 3: Accommodated (See Table 4).

Comment 4: Generalizability is limited because of the relatively young age and high prevalence of CRVHD

Response 4: Dear reviewer: I agree with your point, however since diagnosis in developing countries like Ethiopia is usually established at an advanced stage of the disease, more than half of the patients are above 35 years old. Moreover, almost half of the patients included in this study had heart failure caused by other than CRVRHD.

Comment 5: A prevalence of HFpEF of 66.2% in their group. However, this will be enriched with CRVHD patients (probably MV stenosis).

Response 5: Dear reviewer: thank you for your valuable comment, but as it is indicated in specific valve involved; in this study patients with MS also have other valve lesions. Moreover, the classification of ejection fraction was taken from the patient's medical chart.

Comment 6: Specify the reason for inappropriate dose (suboptimal dose)

Response 6: The dose low is considered as DTP if patients with HFrEF and on ACEIs or beta blockers were not up titrated after carefully consideration of patient status and after excluding any comorbidity or contraindication and the patient at high risk of toxicity due to increased dose (patients who had an organ dysfunction). Unfortunately, as I have raised in the discussion part patients remain in the same dose for several years ( for example patients with IHD and EF of 34 might be on Metoprolol 12.5 mg for years)

Comment 7: Anecdotic interactions are scored as DTPs (such as diuretic with aspirin; or spironolactone with aspirin etc

Response 7: We have made a correction and removed such types of drug interactions

Comment 8: Generalisablity is limited, because of the very high prevalence of untreated CRVHD and young patient age.

Response 8: As per the suggestion; we have made a correction in the discussion part. The main problem is there were only a few studies available and even these studies were done outside Africa, where the cause is not RHD. However we have tried to use these studies only if the problem is almost identical. For example patient with reduced EF and not on cardio protective therapy are considered to have DTP irrespective of the cause of heart failure.

Comment 9: Dual antiplatelet therapy is class I recommended in ACS patients. Therefore, this should not be regarded as a DDI.

Response 9: Accommodated.

Comment 10: Expand Table 4 with patient characteristics, such as age, comorbidities, gender, renal function (eGFR), blood pressure and medication

Response 10: We have made a correction as per recommendation in Table 3. Except eGFR as renal function test is not routinely performed in the outpatient setting.

Comment 11: How many patients have been hospitalized for HF in the past?

Response 11: Dear reviewer, I do have a data that showed only the number of hospitalized patients on the past one year. So I included the frequency (%) in Table 1.

Comment 12: Please have the manuscript reviewed by a native English speaker.

Response12: Accommodated.

###### 

Submitted filename: Response to reviewer comments.docx

###### 

Click here for additional data file.
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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